Tibet Aim Pharm (SZSE:002826) COGS-to-Revenue : 0.20 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm COGS-to-Revenue?

Tibet Aim Pharm's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥29.9 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥148.5 Mil.

Tibet Aim Pharm's COGS to Revenue for the three months ended in Mar. 2025 was 0.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Tibet Aim Pharm's Gross Margin % for the three months ended in Mar. 2025 was 79.87%.

Tibet Aim Pharm COGS-to-Revenue Historical Data

The historical data trend for Tibet Aim Pharm's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm COGS-to-Revenue Chart

Tibet Aim Pharm Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.64

0.56

0.49

0.31

Tibet Aim Pharm Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.40	0.29	0.31	0.26	0.20

Tibet Aim Pharm COGS-to-Revenue Calculation

Tibet Aim Pharm's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	205.253	/	651.884
	=	0.31

Tibet Aim Pharm's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	29.899	/	148.531
	=	0.20

Tibet Aim Pharm (SZSE:002826) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Tibet Aim Pharm's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	29.899 / 148.531
	=	79.87 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Tibet Aim Pharm COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Aim Pharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 610000

Website

http://www.emyy.cn

Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic diseases such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.

Executives

Xu Ke	Director
Peng Hui	Director
Pang Guo Qiang	Directors, executives
Li Qian Jin	Securities Affairs Representative
Liu Hang	Supervisors

Tibet Aim Pharm Headlines

No Headlines